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P U B L I S H E D B Y E L S E V I E RLettersLipoprotein-Associated
Phospholipase A2
Loss-of-Function Variant
and Risk of Vascular
Diseases in 90,000
Chinese AdultsLipoprotein-associated phospholipase A2 (Lp-PLA2)
produces the proinﬂammatory mediators lysophos-
phatidylcholine and oxidized free fatty acids through
hydrolysis of oxidized phospholipids carried on low-
density lipoproteins in atherosclerotic plaques.
Although increased Lp-PLA2 activity has been asso-
ciated with higher risks of occlusive vascular dis-
eases, recent phase III trials of the Lp-PLA2 inhibitor
darapladib, which reduces Lp-PLA2 activity byw60%,
failed to establish a protective role of darapladib for
prevention of major vascular events in patients with
stable coronary heart disease (CHD) or acute coronary
syndrome (1,2).
A V279F loss-of-function variant in the PLA2G7 gene
encoding Lp-PLA2, resulting in 50% lower activity for
each copy of the variant, is common in East Asians (3)
and allows an unbiased assessment of the causal
effects of lifelong lower Lp-PLA2 activity, analogous
to randomized trials of Lp-PLA2 inhibition (4). We
genotyped PLA2G7 V279F (rs76863441) in 91,428
individuals randomly selected from the China
Kadoorie Biobank prospective cohort of 0.5M
participants recruited in 2004 to 2008 from 10
regions of China (5). Follow-up for International
Statistical Classiﬁcation of Diseases and Related
Health Problems 10th Revision–coded incident events
continued to January 1, 2014, through linkage with
morbidity and mortality registries and a nationwide
health insurance system. The pre-speciﬁed primary
endpoint was major vascular events (MVE) (vascular
death, myocardial infarction, stroke), with >90%
power to detect a 20% lower relative risk at p < 0.01.
As a context, the trials were powered to detect 15%
risk reductions, and differences in lifelong exposure
associated with genetic variants would be expected
to have greater effects than intervening for a fewyears in later life (4). Secondary endpoints, for which
power was lower, included major coronary events
(CHD death, myocardial infarction), major occlusive
events (CHD death, myocardial infarction, ischemic
stroke), and stroke subtypes.
The mean baseline age of participants was 51 years
and 40% were men. History of CHD was reported by
3%, stroke or transient ischemic attack by 2%, dia-
betes by 6%, and hypertension by 12% of participants.
Antihypertensive or statin use was reported by 5%
and 0.2% of participants, respectively. The frequency
of PLA2G7 V279F was 5% overall, but varied from 3%
to 7% by region (pheterogeneity <0.0001) and 10.6% of
participants (n ¼ 9,691) had at least 1 loss-of-function
variant. There were no differences in blood pressure,
adiposity, or other baseline characteristics by geno-
type. There was no signiﬁcant association of PLA2G7
V279F with MVE, either overall (odds ratio: 0.98;
95% conﬁdence interval: 0.90 to 1.06; p ¼ 0.63) as
assessed among 7,141 cases and 81,489 controls who
had no prior history of vascular disease, or in speciﬁc
population subgroups deﬁned by sex, 10-year age
group, region, or smoking status. Nor was PLA2G7
V279F associated with any of the components of MVE
(Figure 1).
This is the largest single study to investigate the
associations of PLA2G7 V279F with risk of vascular
diseases, and the results exclude any protective
effect on MVE >10% in this general population. These
ﬁndings are consistent with a previous meta-analysis
of PLA2G7 V279F involving 3,611 East Asian CHD cases
(3), and with the recent ﬁndings from randomized
trials of Lp-PLA2 inhibition (1,2). In contrast with the
trials, MVE in this study predominantly involved
stroke, reﬂecting the differences in cardiovascular
disease rates between East Asian and European
populations.
In conclusion, genetically determined lower Lp-
PLA2 activity appeared to have no substantial causal
effects on major vascular diseases, consistent with
ﬁndings from randomized trials of Lp-PLA2–lowering
therapy. These ﬁndings indicate that it may be
valuable to use functional genetic variants in
large-scale prospective studies with follow-up of a
range of health outcomes to help predict any
beneﬁcial and adverse effects of novel therapeutic
strategies (as well as to identify any potential
FIGURE 1 Association of PLA2G7 V279F With Vascular Diseases
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